Mantle Cell Lymphoma | Specialty

Induction Therapy for MCL

July 26th 2017

Risk Assessment and Prognosis in MCL

July 26th 2017

Biology of Mantle Cell Lymphoma

July 26th 2017

Mantle Cell Lymphoma: Evolution of Therapy

July 26th 2017

Dr. Shah on Emerging Developments in MCL

July 24th 2017

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses some of the emerging developments on the horizon in mantle cell lymphoma (MCL).

Bendamustine Plus Rituximab Maintains Frontline PFS Benefit in MCL, iNHL After 5 Years

July 17th 2017

Five-year follow-up from the BRIGHT study confirmed that bendamustine plus rituximab is associated with improved progression-free survival compared with R-CHOP or R-CVP in patients with mantle cell lymphoma or indolent non-Hodgkin lymphoma.

Ibrutinib Associated With Superior QoL in MCL Compared With Temsirolimus

July 12th 2017

Phase III results from the RAY trial showed that patients with mantle cell lymphoma treated with ibrutinib (Imbruvica) had superior quality of life compared with patients treated with temsirolimus.

TP53 Mutations Have Independent Prognostic Value in MCL

July 11th 2017

Christian Winther Eskelund, MD, discusses TP53 mutations in mantle cell lymphoma.

Dr. Tam on the Toxicities of Ibrutinib Plus Venetoclax in MCL

July 5th 2017

Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses the toxicities of the phase II and phase III studies investigating the combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with mantle cell lymphoma (MCL).

Dr. Eskelund Discusses TP53 Mutated Mantle Cell Lymphoma

June 28th 2017

Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses TP53-mutated mantle cell lymphoma (MCL).

Dr. Eskelund on Study of TP53 Mutations in Mantle Cell Lymphoma

June 24th 2017

Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses a study of TP53 mutations in mantle cell lymphoma.

Combination of Ibrutinib and Buparlisib Shows Promise in MCL and other NHLs

June 16th 2017

Connie Batlevi, MD, PhD, discusses the combination of ibrutinib and buparlisib in MCL.

Ibrutinib-Resistant Patients a Core Challenge in MCL

June 16th 2017

Bijal D. Shah, MD, discusses the current treatment paradigm of MCL, what therapies are moving through the pipeline at a rapid rate, the potential benefit with CAR T-cell therapy, and pivotal biomarker studies currently being conducted.

5-Year Follow-Up Confirms Efficacy of Frontline Bendamustine Plus Rituximab in MCL, iNHL

June 15th 2017

Ian W. Flinn, MD, PhD, discusses the 5-year update of the BRIGHT study in MCL and NHL.

Expert Discusses Ibrutinib/Venetoclax Combo in MCL

June 15th 2017

Constantine S. Tam, MD, discusses phase III PCYC-1143 trial is investigating the combination of ibrutinib and venetoclax as well as the next steps with venetoclax /ibrutinib and other rational combinations in MCL.

Dr. Batlevi on Safety With Ibrutinib/Buparlisib in MCL, FL, and DLBCL

June 14th 2017

Connie Batlevi, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses safety results of a phase I study evaluating the combination of ibrutinib (Imbruvica) and buparlisib in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).

Dr. Tam on the Combination of Ibrutinib Plus Venetoclax in Mantle Cell Lymphoma

June 14th 2017

Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses the phase II and phase III studies investigating the combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with mantle cell lymphoma (MCL).

Dr. Hamlin on Early Study of Ibrutinib/Buparlisib in MCL, FL, and DLBCL

June 12th 2017

Paul A. Hamlin, MD, of Memorial Sloan Kettering Cancer Center, discusses a phase I dose-escalation study of buparlisib plus ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).

Expert Explains Evolution of MCL Treatment

May 30th 2017

Peter Martin, MD, discusses the evolution of treatment and ongoing research for patients with mantle cell lymphoma.

Dr. Martin on the Role of Transplant in Mantle Cell Lymphoma

May 23rd 2017

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the role of transplant in the field of mantle cell lymphoma (MCL).